First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
NCT04725474
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
263
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL:
visugromab (CTL-002)
Sponsor
CatalYm GmbH